Amarin

Amarin & Celsion: Post-Earnings Roundup

Amarin & Celsion: Post-Earnings Roundup

Seeking Alpha

Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground

Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground

Seeking Alpha

No Fat in This Drug Launch

No Fat in This Drug Launch

Motley Fool

Risky Amarin Sets Its Cash Pile On Fire

Risky Amarin Sets Its Cash Pile On Fire

Seeking Alpha

Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits

Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits

TheStreet.com

Amarin's Fish Oil Pill Faces Even More Exclusivity Risks

Amarin's Fish Oil Pill Faces Even More Exclusivity Risks

TheStreet.com

3 Horrendous Health-Care Stocks This Week

3 Horrendous Health-Care Stocks This Week

Motley Fool

By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa

By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa

Seeking Alpha

No NCE Decison For Amarin's Vascepa: The Launch Trudges Along

No NCE Decison For Amarin's Vascepa: The Launch Trudges Along

Seeking Alpha